Last reviewed · How we verify
NCT00074672
Relationship Between Sensory and Motor Systems in Restless Leg Syndrome
trial in Restless Legs Syndrome in 45 participants. Completed in 14 April 2009.
Quick facts
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 45 |
| Start date | 12 December 2003 |
| Estimated completion | 14 April 2009 |
| Sites | 1 location across United States |
Conditions studied
- Restless Legs Syndrome — all drugs for Restless Legs Syndrome →
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Who can join
Adults 18 to 80, any sex, with Restless Legs Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will explore what occurs between sensory and motor systems in restless legs syndrome (RLS). Patients with RLS have uncomfortable sensations in the legs, usually in the evening or early part of the night. Most patients also have periodic involuntary leg movements. The condition tends to worsen over time, resulting in severe discomfort and sleep disturbances. Healthy normal volunteers and patients with RLS between 18 and 80 years of age may be eligible for this study. All candidates will be screened with a medical history, physical and neurological evaluations, electroymogram (measure of muscle activity), overnight sleep study, electrocardiogram (ECG, measurement of the electrical activity of the heart), and blood and urine tests. They may also have brain or spine magnetic resonance imaging (MRI) or computerized tomography (CT) scans and a chest X-ray. Participants must stop taking all medications prohibited by the study for 2 days or more before the study starts and throughout its duration. Participants will undergo prepulse inhibition tests to assess nervous system function. The participant sits comfortably in a quiet room. Several cables are attached to the face and legs using a special cream that conducts electrical signals through the cables to recording equipment. Nervous system activity is evaluated while the subject is at rest and after sensory stimulation (stimulating the nerves in the legs and face with a very brief electrical current of mild to moderate intensity). At times, the subject receives a short, mild sound stimulation delivered through earphones. The testing session takes 4 to 6 hours.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00074672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Restless Legs Syndrome
Currently open trials in the same condition.
- NCT06889324 — Efficacy of Vibration Therapy on Restless Legs Syndrome and Sleep Disturbances Among Patients Undergoing Hemodialysis · NA · active not recruiting
- NCT06866132 — Response to an Investigational Device in Patients With Restless Legs Syndrome · NA · active not recruiting
- NCT06684782 — Prevalence and Characteristics of Restless Leg Syndrome in Thai Patients With Parkinson's Disease · recruiting
- NCT06806891 — Restless Leg Syndrome: Is There a Response to Buddhist Walking Meditation in Hemodialysis · NA · recruiting
- NCT06570941 — Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome · Phase 1, PHASE2 · active not recruiting
Other National Institute of Neurological Disorders and Stroke (NINDS) trials
Trials by the same sponsor.
- NCT07137442 — Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques · recruiting
- NCT02522611 — Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain · Phase 1, PHASE2 · not yet recruiting
- NCT07511049 — Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study · Phase 2 · not yet recruiting
- NCT07416188 — Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma · Phase 1, PHASE2 · not yet recruiting
- NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00074672 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Neurological Disorders and Stroke (NINDS)
- Last refreshed: 2 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00074672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing